30 closest matches · ranked by relevance
Metastatic Carcinoma in the Adrenal Cortex · Stage III Adrenal Cortex Carcinoma AJCC v8 · Stage IV Adrenal Cortex Carcinoma AJCC v8
Primary: Progression-free Survival (PFS) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 Criteria — 72.2 precentage of participants
Adrenal Cortex Neoplasms
Primary: Percentage of Participants With a Partial or Complete Response — 4; 6 Percentage of participants
Adrenocortical Carcinoma · Peritoneal Carcinomatosis
Primary: Intraperitoneal Progression Free Survival (PFS) — 19 Months
Adrenocortical Carcinoma
Primary: Assessment of Clinical Benefit Due to Treatment With Sunitinib — 5 Participants
Stage I Adrenal Cortical Carcinoma AJCC v7 · Stage II Adrenal Cortical Carcinoma AJCC v7 · Stage III Adrenal Cortical Carcinoma AJCC v7
Primary: Five Year Event-free Survival (EFS) — 0.86; 0.53; 0.51 Estimated probability five year EFS — p=0.44
Adrenal Cortex Neoplasms
Primary: Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC) — 0; 0; 13; 0 Participants
Carcinoma, Adrenal Cortical
Primary: Overall Survival — 108; 124 participants
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Metastatic Gastrointestinal Carcinoid Tumor · Pulmonary Carcinoid Tumor · Recurrent Gastrointestinal Carcinoid Tumor
Primary: Objective Tumor Response Rate (Defined as Partial or Complete Response as Defined by the RECIST Criteria) — 2 participants
Cancer · Prostate Neoplasms
Primary: Prostate Tissue DHT — 0.03; 0.06; 0.03 ng/g
Hypercortisolism
Primary: Change in Average 24-hour SBP — -5.56; -2.89 mm Hg — p=0.4160
Carcinoma, Large Cell · Neuroendocrine Tumors
Primary: Percentage of Participants Progression-free — 49.0 Percentage of participants
Recurrent Adrenocortical Carcinoma · Stage III Adrenocortical Carcinoma · Stage IV Adrenocortical Carcinoma
Primary: The Proportion of Patients Who Achieve a Confirmed Objective Response to Treatment, Either Partial Response (PR) or Complete Response (CR) as Defined by Response…
Neuroendocrine Tumor · Anaplastic Thyroid Cancer · Adenocarcinoma
Primary: Objective Response Rate (ORR) — 0; 2; 2; 2 Participants
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)
Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants
Endogenous Cushing's Syndrome
Primary: Normalization in Urinary Free Cortisol in Patients With Endogenous Cushing's Syndrome. — .30 proportion of subjects meeting endpoint — p=0.0154
Recurrent Oral Cavity Adenoid Cystic Carcinoma · Recurrent Salivary Gland Carcinoma · Salivary Gland Adenoid Cystic Carcinoma
Primary: Confirmed Response Rate (Complete Response + Partial Response) According to RECIST Version 1.1 — 0 percentage of patients
Renal Cell Carcinoma
Primary: PFS (Progression-Free Survival) — 27.71 Weeks
Neoplasms, Unknown Primary
Primary: Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death — 7.4; 8.5 months
Adrenal Tumors
Primary: Increase in Catecholamine
Carcinoid Tumors
Primary: Symptom Control (Diarrhea/Flushing) Using a Patient Symptom Diary — 3; 9; 32 participants
Congenital Adrenal Hyperplasia · 21-Hydroxylase Deficiency · Adrenogenital Syndrome
Primary: Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose)…
Adrenal Insufficiency
Primary: Serum Cortisol Concentration up to 240 Minutes — 575.8 nmol/L
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Neuroendocrine Tumor · Carcinoid Tumor · Pancreatic Neuroendocrine Tumor
Primary: Objective Response Rate — 0.0 percentage of patients
Neuroendocrine Tumors · Carcinoma, Small Cell Lung · Neuroendocrine Carcinoma
Primary: Phase 1: Maximum Tolerated Dose of PEN-221 and Recommended Phase 2a Dose (RP2D) — 18.0 mg
Carcinoid Tumors
Primary: Progression-Free Survival (PFS) — 14.2 months